JOHN HOPE FRANKLIN CENTER

Dr. Daniel George presented real-world outcomes of olaparib monotherapy in mCRPC patients with HRR mutations at the 2024 SUO meeting. Median treatment duration, PFS, and OS were 4.6, 4.5, and 16.5 months, respectively, similar to PROfound trial results. Early biomarker testing and treatment initiation are crucial for better outcomes.

Lead exposure from car exhaust in the 20th century caused up to 151 million cases of mental health disorders in Americans, with those born before 1996, especially in the 1960s-70s, at risk. Leaded gas use altered mental health, increasing depression, anxiety, and ADHD rates, and likely impacted personality and life success. The study, published in the Journal of Child Psychology and Psychiatry, highlights the long-term effects of historical lead exposure.

PCORI approves $14.4 million for UNC researcher Michael D. Kappelman, MD, MPH, to study new treatment options for pediatric inflammatory bowel diseases (PIBD) using PCORnet, aiming to generate real-world evidence on the effectiveness and safety of off-label medications for patients unresponsive to anti-TNF treatments.

A twice-yearly HIV vaccine, lenacapavir, has shown 100% effectiveness in preventing HIV in women and nearly as well in men. Gilead plans to allow generic versions in 120 high-HIV countries but excludes Latin America, where rates are increasing. UNAIDS' Winnie Byanyima calls the vaccine 'unprecedented' and crucial for ending the epidemic. Gilead aims to expand access globally, but concerns remain over exclusion of Latin American countries, where stigma and rising HIV rates pose challenges.

New FDA rules mandate clearer drug ad risk disclosures, impacting TV and radio ads. Despite industry adoption, social media influencers promote drugs with little oversight. A proposed bill aims to regulate online drug promotions, requiring risk disclosure and payment transparency.

Andrew C. Peterson, MD, MPH, discusses how the Artificial Urinary Sphincter improves depression, anxiety, and emotional health in men with stress urinary incontinence, emphasizing the importance of considering patient-reported outcomes beyond physical metrics in clinical practice.

At the Clinical Trials in Alzheimer’s Disease conference, scientists discussed making anti-Aβ monoclonals safer and more effective, shared Phase 1 trial findings on new approaches like gene silencing and gene therapy, and explored immune checkpoint inhibitors and intranasal insulin. Mivelsiran, a gene silencing approach, showed promising results in early AD and CAA, while LX1001 gene therapy boosted CSF ApoE2 and stabilized AD biomarkers. Intranasal insulin reduced systemic inflammation, and combination therapies targeting multiple AD mechanisms were proposed.

FDA approves cannabis study on 320 veterans with PTSD, potentially impacting the cannabis sector. MAPS leads the $13 million trial, focusing on high-THC cannabis's therapeutic value. Results could take years to affect the market.

FDA approves cannabis study on 320 veterans with PTSD, potentially impacting the cannabis sector. MAPS leads the $13 million trial, focusing on high-THC cannabis's therapeutic value.

Sony and Nature announce shortlist for Sony Women in Technology Award, recognizing early to mid-career researchers with $250,000 each. Seven finalists from diverse fields are selected, with winners to be announced on February 5, 2025 in Tokyo.